Penumbra (PEN) Peer Comparison
$321.14
$1.02
(0.32%)
As on 15-Oct-2026 16:16EDT
Market cap
$12,507 Mln
Revenue (TTM)
$1,505 Mln
P/E Ratio
78
P/B Ratio
8.2
Div. Yield
0 %
Edit
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
12,507 | 10,508 | 11,040 | 10,599 | 9,762 |
Revenue ($ Mln) |
1,505 | 617 | 785 | 6,561 | 2,589 |
Net Profit ($ Mln) |
160.59 | -75.13 | 41.54 | -578.00 | 222.40 |
Net Margin (%) |
10.67 | -12.18 | 5.29 | -8.81 | 8.59 |
RoE (%) |
10.86 | -9.26 | 1.97 | -10.33 | 3.04 |
Price to Earnings |
78.01 | -- | 238.19 | -- | 46.27 |
Price-To-Book |
8.22 | 11.93 | 4.93 | 1.77 | 1.36 |
Income Statement ($ Mln)
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,504.87 | 616.91 | 785.10 | 6,561.10 | 2,589.30 |
|
Cost of Revenue
|
483.98 | 184.88 | 384.30 | 4,473.00 | 1,245.50 |
|
Gross Profit
|
942.44 | 443.88 | 347.62 | 2,139.40 | 1,343.60 |
|
Operating Expenses
|
833.56 | 520.41 | 335.50 | 2,373.70 | 1,108.90 |
|
Operating Profit (EBIT)
|
187.34 | -88.38 | 65.30 | -285.60 | 235.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
203.83 | -74.89 | 52.15 | -472.00 | 350.40 |
|
Provision for Tax
|
43.24 | 0.24 | 10.61 | 106.00 | 128.00 |
|
Profit after Tax (Net Income)
|
160.59 | -75.13 | 41.54 | -578.00 | 222.40 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
93.19 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,530.77 | 825.55 | 2,112.03 | 5,630.20 | 7,173.90 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
210.18 | 86.01 | 705.49 | 4,583.70 | 2,116.80 |
|
Current Liabilities
|
233.78 | 118.51 | 132.66 | 1,382.00 | 961.30 |
|
Total Liabilities
|
1,826.52 | 1,041.37 | 2,949.70 | 11,794.70 | 10,576.50 |
Assets ($ Mln)
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
630.60 | 355.40 | 1,749.63 | 9,133.70 | 7,231.50 |
|
Current Assets
|
1,344.12 | 674.67 | 1,200.55 | 2,462.20 | 3,020.50 |
|
Total Assets
|
1,826.52 | 1,041.37 | 2,949.70 | 11,794.70 | 10,576.50 |
|
Total Debt*
|
212.71 | 78.80 | 690.94 | 3,697.80 | 1,203.70 |
|
Net Current Assets
|
1,110.35 | 556.16 | 1,067.90 | 1,080.20 | 2,059.20 |
Cashflow ($ Mln)
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
238.66 | 136.05 | 117.42 | 623.80 | 532.20 |
|
Cash Flow from Investing Activities
|
-404.59 | -13.44 | -298.47 | -130.50 | -189.70 |
|
Cash from Financing Activities
|
26.53 | 6.80 | -15.21 | -409.40 | -283.20 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
11.76 | -4.99 | 1.79 | -5.43 | 8.98 |
|
ROE (%)
|
10.86 | -9.26 | 1.97 | -10.33 | 3.04 |
|
ROA (%)
|
7.95 | -6.71 | 1.36 | -4.08 | 2.02 |
|
EBIT Margin (%)
|
13.63 | -1.34 | 9.87 | -4.47 | 15.42 |
|
Net Margin (%)
|
10.67 | -12.18 | 5.29 | -8.81 | 8.59 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
17.55 | -4.28 | 16.49 | -1.57 | 1.37 |
|
EBIT Growth (%)
|
17.49 | 89.59 | 920.91 | -129.16 | -20.02 |
|
Net Profit Growth (%)
|
8.72 | 11.20 | 400.42 | -184.08 | -30.32 |
|
EPS Growth (%)
|
8.12 | 16.01 | 394.30 | -184.11 | -29.66 |
|
Book Value Growth (%)
|
17.33 | 2.26 | 2.16 | -9.82 | 2.19 |
Valuation Ratios
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
68.93 | -47.60 | 189.42 | -14.68 | -- |
|
Price / Book Value
|
8.58 | 2.60 | 4.40 | 1.40 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
53.25 | 436.68 | 50.32 | 81.94 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.26 | 0.65 | 0.11 |
|
Short term debt to equity ratio
|
0.01 | 0.01 | 0.01 | 0.01 | 0.06 |
|
Current Ratio
|
5.75 | 5.69 | 9.05 | 1.78 | 3.14 |
|
Quick Ratio
|
3.86 | 5.25 | 7.64 | 1.18 | 2.33 |
|
Interest Coverage
|
157.91 | -24,962.33 | 1.92 | -1.64 | 8.18 |
Operating Efficiency Ratios
| Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
12.65 | 8.21 | 20.09 | 17.36 | 17.06 |
|
Asset Turnover
|
0.74 | 0.55 | 0.26 | 0.46 | 0.24 |
|
Receivable days
|
46.54 | 48.40 | 72.41 | 58.79 | 65.39 |
|
Inventory Days
|
331.92 | 128.01 | 146.53 | 64.13 | 221.09 |
|
Payable days
|
26.16 | 23.54 | 29.05 | 58.13 | 37.02 |
|
Cash Conversion Cycle
|
352.30 | 152.87 | 189.88 | 64.79 | 249.46 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
